Rush Limbaugh Has Embryonic Stem Cell Therapy in Mexico

Funny story written by Felix Minderbinder

Thursday, 26 October 2006

image for Rush Limbaugh Has Embryonic Stem Cell Therapy in Mexico
A HCDGMT sufferer

MEXICO CITY (Reuters)-- Controversial right-wing radio host Rush Limbaugh has undergone an experimental first-of-a-kind embryonic stem-cell therapy at an private clinic in Mexico to treat his lifelong neurodegenerative disease "Hypercerebraldegenero-Graymattertrophism" (HCDGMT), a rare genetic disease which is related to Parkinson's and Alzheimer's diseases but which is far more severe.

"Using embryonic stem cells, we appear to have managed to slow the progression of this dreaded condition in this subject," said Jose Jimenez, a doctor at the clinic. "The therapy has even restored some of Limbaugh's lost brain with new embryonic nerve cells."

HCDGMT victims slowly lose their higher cognitive functions and become profane, illogical, warmongering, rabid fundamentalist neoconservatives. They usually display abnormally long tongues.

The disease is progressive and runs in families, particularly in the Washington, DC, Missouri and Houston areas. But with the new treatment there is now the faint hope for a cure, where previously there was none.

HCDGMT victims were formerly forced to enter Republican politics or become electronic media hosts.

"We are pleased at the initial success of this treatment," added Jimenez, "Even for an asshole like that one."

Further treatment of other HCDGMT victims who are known to exist in Texas, in the Washington area and in the White House are being planned.

The funny story above is a satire or parody. It is entirely fictitious.

Do you dream of being a comedy news writer? Click here to be a writer!

Comedy spoof news topics

Related Funny Stories…

Mailing List

Get Spoof News in your email inbox!

Go to top
readers are online right now!
Globey, The Spoof's mascot

We use cookies to give you the best experience, this includes cookies from third party websites and advertisers.

Continue ? Find out more